A central question in biodiversity governance is how the international community will regulate the conservation and equitable sharing of benefits from the utilization of marine genetic resources in areas beyond national jurisdiction (ABNJ). The equity question concerns how to secure benefits from global commons resources for all, not only for financially and technologically strong actors. The access and benefit-sharing (ABS) principles set out in the Convention on Biological Diversity (CBD) (CBD, 1993) and elaborated in its 2014 Nagoya Protocol are decisive rules on these equity concerns. This chapter examines strategies of biotechnology corporations regarding the ABS issue, including how it is discussed in the UN Convention on the Law of the Sea negotiations.